Filing Flows › 8-K events › Jasper Therapeutics

Jasper Therapeutics: other events

Form 8-K filed Nov 9, 2026 · items 8.01

Mergers and acquisitionsJASPER THERAPEUTICS, INC. ANNOUNCES RESULTS OF THE

What the filing says

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the results of its offer to purchase (the “Offer”) all of its outstanding warrants to purchase sha

Read the filing on SEC EDGAR →

What usually followsAcross 44,918 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Jasper Therapeutics’s other material 8-Ks

• Nov 4, 2026 — FDA decisions Jasper Therapeutics Announces 1-for-30 Reverse Stock Split

Other recent mergers and acquisitions

• loanDepot Nov 9, 2026
• Strive Nov 9, 2026
• CDT Equity Nov 9, 2026
• CorMedix Nov 9, 2026
• Somnigroup International Nov 9, 2026
• Heron Therapeutics Nov 9, 2026
• NRG Energy Nov 9, 2026
• Charles River Laboratories International Nov 9, 2026
• Starry Sea Acquisition Nov 6, 2026
• Kontoor Brands Nov 6, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.